HomeCompareBDX vs HRC

BDX vs HRC: Dividend Comparison 2026

BDX yields 2.27% · HRC yields 11.38%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 HRC wins by $2.23M in total portfolio value
10 years
BDX
BDX
● Live price
2.27%
Share price
$154.69
Annual div
$3.51
5Y div CAGR
13.5%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$26.9K
Annual income
$1,058.14
Full BDX calculator →
HRC
HRC
● Live price
11.38%
Share price
$155.96
Annual div
$17.74
5Y div CAGR
40.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$2.26M
Annual income
$1,423,429.65
Full HRC calculator →

Portfolio growth — BDX vs HRC

📍 HRC pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBDXHRC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BDX + HRC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
BDX pays
HRC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BDX
Annual income on $10K today (after 15% tax)
$192.91/yr
After 10yr DRIP, annual income (after tax)
$899.42/yr
HRC
Annual income on $10K today (after 15% tax)
$966.88/yr
After 10yr DRIP, annual income (after tax)
$1,209,915.20/yr
At 15% tax rate, HRC beats the other by $1,209,015.78/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BDX + HRC for your $10,000?

BDX: 50%HRC: 50%
100% HRC50/50100% BDX
Portfolio after 10yr
$1.14M
Annual income
$712,243.89/yr
Blended yield
62.39%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on BDX right now

BDX
Analyst Ratings
16
Buy
16
Hold
1
Sell
Consensus: Buy
Price Target
$193.80
+25.3% upside vs current
Range: $170.00 — $215.00
Altman Z
2.1
Piotroski
8/9
HRC
Analyst Ratings
7
Buy
12
Hold
1
Sell
Consensus: Hold
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BDX buys
12
HRC buys
0
PoliticianChamberTickerTypeAmountDate
Ro Khanna🏢 House$BDX▲ Buy$1,001 - $15,0002025-09-29
Lisa McClain🏢 House$BDX▼ Sell$1,001 - $15,0002025-06-24
Lisa McClain🏢 House$BDX▲ Buy$1,001 - $15,0002025-06-17
Rob Bresnahan🏢 House$BDX▲ Buy$1,001 - $15,0002025-05-15
Thomas H. Kean🏢 House$BDX▲ Buy$1,001 - $15,0002025-05-13
Rob Bresnahan🏢 House$BDX▼ Sell$1,001 - $15,0002025-04-08
Jefferson Shreve🏢 House$BDX▼ Sell$15,001 - $50,0002025-03-05
William R. Keating🏢 House$BDX▼ Sell$1,001 - $15,0002024-09-11
Ro Khanna🏢 House$BDX▼ Sell$1,001 - $15,0002024-09-09
John James🏢 House$BDX▼ Sell$1,001 - $15,0002024-09-04
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBDXHRC
Forward yield2.27%11.38%
Annual dividend / share$3.51$17.74
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR13.5%40.3%
Portfolio after 10y$26.9K$2.26M
Annual income after 10y$1,058.14$1,423,429.65
Total dividends collected$5.7K$2.14M
Payment frequencyquarterlyquarterly
SectorHealthcareStock
Analyst consensusBuyHold

Year-by-year: BDX vs HRC ($10,000, DRIP)

YearBDX PortfolioBDX Income/yrHRC PortfolioHRC Income/yrGap
1← crossover$10,958$257.59$12,296$1,595.93$1.3KHRC
2$12,024$299.40$15,730$2,573.05$3.7KHRC
3$13,214$348.50$21,147$4,316.00$7.9KHRC
4$14,545$406.26$30,235$7,608.15$15.7KHRC
5$16,038$474.35$46,615$14,263.36$30.6KHRC
6$17,715$554.80$78,712$28,834.27$61.0KHRC
7$19,606$650.06$148,063$63,841.01$128.5KHRC
8$21,741$763.12$315,890$157,462.80$294.1KHRC
9$24,161$897.64$778,498$440,495.17$754.3KHRC
10$26,910$1,058.14$2,256,422$1,423,429.65$2.23MHRC

BDX vs HRC: Complete Analysis 2026

BDXHealthcare

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is based in Franklin Lakes, New Jersey.

Full BDX Calculator →

HRCStock

Hill-Rom Holdings, Inc. operates as a medical technology company worldwide. It operates in Patient Support Systems, Front Line Care, and Surgical Solutions segments. The company offers medical surgical beds, intensive care unit beds, and bariatric patient beds, lifts and other devices, non-invasive therapeutic products and surfaces, and information technologies and software solutions, as well as sells equipment service contracts for its capital equipment. It also provides patient monitoring and diagnostics products, such as patient exam and diagnostics, patient monitoring, diagnostic cardiology, vision screening, and diagnostics products; and respiratory health products comprising Vest System, VitalCough System, MetaNeb System, Monarch, and Life2000 systems to assist patients in the mobilization of retained blockages. In addition, the company offers surgical solutions that include surgical tables, lights, and pendants; positioning devices for use in shoulder, hip, spinal, and lithotomy surgeries, as well as platform-neutral positioning accessories for operating room tables. Further, it is involved in the sales and rental of products to acute and extended care facilities through direct sales force and distributors; sales and rental of products directly to patients in the home; and sales to primary care facilities through distributors. Additionally, the company offers continuum of clinical care, including acute care and primary care, as well as clinical research organizations. Hill-Rom Holdings, Inc. was founded in 1969 and is headquartered in Chicago, Illinois.

Full HRC Calculator →
📬

Get this BDX vs HRC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BDX vs SCHDBDX vs JEPIBDX vs OBDX vs KOBDX vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.